文献速递青光眼角膜与眼表疾病

Preserflo MicroShunt 植入术后角膜内皮细胞密度变化

Corneal endothelial cell density changes after Preserflo MicroShunt implantation.
PubMed 文献 · Br J Ophthalmol · 2026-07-22

这项回顾性研究纳入104眼接受Preserflo MicroShunt(PMS)植入(70眼单纯PMS,34眼联合白内障超声乳化),随访至少12个月。PMS植入后12个月内角膜内皮细胞密度(CECD)下降,单纯PMS组年损失估计为7.3%±11.9%,联合手术组为8.0%±17.2%(p=0.47)。较窄的管-角膜角(TCA)(p=0.01)和较高的术前眼压(p=0.04)与更大的CECD损失显著相关。

要点

  • PMS植入术后12个月内CECD下降,单纯组年损失7.3%±11.9%,联合白内障组8.0%±17.2%。
  • 较窄的管-角膜角(TCA)(p=0.01)与更大CECD损失显著相关。
  • 较高的术前眼压(p=0.04)与更大CECD损失显著相关。

核心结论

  • PMS植入与12个月内CECD下降相关。
  • 较窄的TCA和较高的术前眼压是CECD损失的显著预测因素。

研究设计与样本

  • 回顾性研究纳入2023年3月至2024年4月接受PMS植入(伴或不伴联合白内障手术)且术后随访至少12个月的患者。
  • 共纳入104眼,其中单纯PMS组70眼,联合超声乳化组34眼。
  • 术前及术后3、6、12个月测量CECD,主要结局为PMS植入后CECD变化。

主要发现

  • 单纯PMS组基线CECD为2312.9±501.7 cells/mm²,术后3、6、12个月分别为2253.7±530.9、2234.6±528.5、2149.2±537.5 cells/mm²。
  • 联合超声乳化组基线CECD为2615.0±365.5 cells/mm²,术后3、6、12个月分别为2354.4±424.6、2374.6±458.9、2357.6±508.7 cells/mm²。
  • 估计年CECD损失单纯PMS组为7.3±11.9%,联合组为8.0±17.2%(p=0.47)。

关键数值与推荐

  • 多因素logistic回归显示较窄的TCA(p=0.01)和较高的术前眼压(p=0.04)与更大CECD损失显著相关。

临床怎么用

  • PMS植入术后应监测角膜内皮细胞密度变化。
  • 对于管-角膜角较窄或术前眼压较高的患者,需关注CECD损失风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate the effect of Preserflo MicroShunt (PMS) implantation on corneal endothelial cell density (CECD) and to identify factors associated with CECD loss. METHODS: This retrospective study included patients who underwent PMS implantation, with or without combined cataract surgery, between March 2023 and April 2024, with a minimum of 12 months of postoperative follow-up. CECD was measured preoperatively and at 3, 6 and 12 months postoperatively. The primary outcome was the change in CECD after PMS implantation. Secondary analyses included linear regression to estimate annual CECD loss and logistic regression to identify factors associated with CECD reduction. RESULTS: In total, 104 eyes (70 PMS alone, 34 combined with phacoemulsification) were included. Mean CECD (cells/mm²) in PMS-alone group and combined-with-phacoemulsification group were 2312.9±501.7 and 2615.0±365.5 at baseline, 2253.7±530.9 and 2354.4±424.6 at 3 months postoperatively, 2234.6±528.5 and 2374.6±458.9 at 6 months postoperatively and 2149.2±537.5 and 2357.6±508.7 at 12 months postoperatively, respectively. The estimated annual CECD loss was 7.3±11.9% in the PMS-alone group and 8.0±17.2% in the combined-with-phacoemulsification group (p=0.47). Multivariate logistic regression revealed that a narrower tube-cornea angle (TCA) (p=0.01) and higher preoperative IOP (p=0.04) were significantly associated with greater CECD loss. CONCLUSIONS: PMS implantation was associated with CECD reduction over 12 months. A narrower TCA and higher preoperative intraocular pressure were significant predictors of CECD loss.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Baba T, Baba O, Hirose K, et al. Corneal endothelial cell density changes after Preserflo MicroShunt implantation. Br J Ophthalmol. 2026. PMID: 41545172. doi:10.1136/bjo-2025-328495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。